Psychedelic Treatment for Depression Moving Toward Clinical Trials
January 25th, 2022
Exclusive, News, Top News
Depression, or more formally Major Depressive Disorder (MDD), is a widespread and growing problem across the globe. In the United States in 2019, 19.4 million adults (7.8% of all adults) were estimated to have a major depressive episode. About two-thirds of these people received treatment of some sort, and the most effective treatments produce roughly 30 to 40 percent remission rates. As a result of the pandemic and related stresses, prevalence of depressive symptoms in US adults shot up to a staggering 27.8% in 2020, and 32.8% in 2021.
The opportunity is enormous for those able to develop better forms of treatment for MDD. Axsome Therapeutics’ (NASDAQ: AXSM) lead drug candidate, AXS-05, showed 52.5% remission after 6 weeks of treatment and even higher rates with longer treatment periods. In 2020, the company estimated peak sales of AXS-05 for the treatment of MDD could range from $1 billion to $3 billion annually. AXS-05 has been awaiting FDA approval since August, 2021.
Meanwhile, psychedelic therapies for MDD have shown great promise. A quick search of the Internet will reveal that much. But there are major barriers to approval and widespread acceptance of these therapies. First, many of the drugs are Schedule 1 substances subject to strict federal regulation. Second, many of them involve intense hallucinogenic experiences that make many people hesitant to try them while requiring a long period of clinical supervision during treatment. Third, most psychedelic substances are in the public domain and can’t be patented, meaning that companies may not be motivated to spend the money and time necessary to bring them through trials and to the market.
BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FRA: NPAU) has developed a drug candidate that may be a viable alternative for the treatment of neuro-psychiatric and neurological disorders. BetterLife’s BETR-001 is a synthesized derivative of LSD that demonstrates the benefits of its ‘parent’ but without the hallucinogenic side effects and regulatory hurdles possible with other psychedelic compounds. BetterLife has applied for a comprehensive patent, and recent developments show the company proceeding through preclinical studies to an anticipated Phase 1 trial in Q3 2022.
How does BetterLife Pharma potentially improve existing psychedelic therapies? Click to see CEO Dr. Ahmad Doroudian discuss the company’s innovations.
Recent Developments Promising
BetterLife Pharma recently announced two positive developments for the advancement of BETR-001. First, the company obtained good results from its preclinical work that was focused on bioavailability and the effect food would have on the uptake of the drug. Results showed the presence of food, or the lack thereof, did not significantly affect bioavailability, with systemic circulation of the drug reported around 60%. Importantly, maximum concentration was reached around 30 minutes after administration indicating quick uptake. On the other end, the drug was shown to leave the system at a consistent rate, suggesting that drug accumulation and possible toxicity are not likely.
“We are very pleased with the results of the first oral PK study for BETR-001 drug manufactured by BetterLife’s patented synthesis and formulation process. Although 2-bromo-LSD has been tested in rodents and human studies in the past, this is the first study to characterize its PK profile in vivo”, stated BetterLife’s Chief Executive Officer, Dr. Ahmad Doroudian. He added, “These data, together with the ongoing IND-enabling nonclinical toxicology studies, will support the filing of BETR-001’s IND application with the FDA and initiation of human clinical trials in H2 2022.”
What Conditions Is BetterLife Pharma Looking To Treat With Its Novel Therapeutics?
In the second bit of news, BetterLife announced generally positive feedback from its pre-investigational new drug (pre-IND) meeting with the FDA. The pre-IND process helps the company prepare its IND filing, necessary for the initiation of clinical trials, and gives the FDA a look at the company’s plans for the drug.
CEO Dr. Ahmad Doroudian stated, “The response from the FDA confirms that our current program will support the filing of BETR-001’s IND application and initiation of human clinical trials by the third quarter of this year. Being a non-hallucinogenic derivative of LSD makes BETR-001 a unique molecule with therapeutic potential for the treatment of debilitating psychiatric and neurological disorders with high unmet need, such as major depressive disorders and cluster headaches. Our team is fully dedicated to start the human clinical trials in the United States by early second half of this year.”
There are several upcoming events and developments that could work as catalysts for BetterLife Pharma. More data will likely be announced prior to the company’s anticipated IND filing and commencement of clinical trials for BETR-001, targeted for Q3 2022. On top of the treatment for MDD discussed above, BetterLife is eyeing cluster headaches as another indication to be investigated in the trials.
What Kind Of Developments Could BetterLife Pharma See In The Coming Months?
The company is also looking for results from its Phase 2 inhalable interferon/COVID-19 trial in Chile. If the results there look good, BetterLife plans to move quickly into an IND application with the FDA in the United States that would set in motion a US-based Phase 2 trial of the promising treatment.
With the COVID and depression treatments taking center stage recently, BetterLife’s Interferon/HPV trial program has been tabled to an extent. Phase 2b trials will be the next step in this drug’s development. The company is exploring options to move both the HPV and COVID drugs, both based on interferon, into a new vehicle that could create significant shareholder value in the short term. Options range from partnering with other drug development companies to creating a subsidiary or separate entity entirely.
Overall, BetterLife Pharma represents a compelling opportunity in novel therapeutic development. It’s compounds are patentable improvements on naturally occurring substances with the potential to treat conditions like MDD, migraines, and even COVID-19. Stay tuned as BetterLife makes its way through this pivotal year in the company’s development.
BetterLife Pharma is focused on developing and commercializing compounds to treat neurological and neuro-psychiatric disorders as well as viral infections.
Interested readers are encouraged to contact the company via Manager of Investor Relations David Melles, at David.Melles@blifepharma.com.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.